cash runway
The latest news about cash runway: headlines, AI summaries and the full story from every source.
- Taysha Gene Therapies Reports Q3 2026 GAAP EPS of -$0.10, Exceeding Estimates
- PolyPid Reports Q3 2026 Financial Results and D-PLEX100 Regulatory Progress
- SpyGlass Pharma Reports Q3 GAAP EPS of -$0.73, Missing Estimates by $0.09
- Kura Oncology Reports Q3 2026 Results with Strong KOMZIFTI Revenue Growth
- Inovio Reports Q3 2026 Financial Results and VOCERYQ Commercialization Roadmap
- BridgeBio Oncology Therapeutics Reports Q3 GAAP EPS of -$0.43, Exceeding Estimates
- Alto Neuroscience Reports Q3 GAAP EPS of -$0.54, Exceeding Estimates
- Atara Biotherapeutics Reports Q3 Earnings Beat with Improved EPS and Revenue
- Hemab Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- Black Diamond Therapeutics Reports Q3 GAAP EPS of -$0.17 and Strong Cash Position
- Immatics Reports Q3 Financial Results and Cash Runway Extension
- PepGen Reports Q3 GAAP EPS of -$0.28, Slightly Missing Estimates
- Opus Genetics Reports Q3 Earnings Miss on Lower Revenue and Negative EPS
- Ovid Therapeutics Reports Q3 GAAP EPS of -$0.10, Missing Estimates by $0.02
- Trevi Therapeutics Reports Q3 2026 Financial Results and Clinical Trial Updates
- Definium Therapeutics Reports Positive Phase 3 Clinical Results and Strong Cash Position for Q3 2026
- Atea Pharmaceuticals Reports Positive Phase 3 C-BEYOND Trial Results and Q3 2026 Financials
- MBX Biosciences Reports Q3 GAAP EPS of -$1.29 and Strong Cash Position
- Annexon Biosciences Reports Third Quarter GAAP EPS of -$0.25 and Updates Clinical Trial Progress
- Structure Therapeutics Reports Q3 Financial Results and Clinical Updates
- Tonix Pharmaceuticals Reports Q3 2026 Revenue Surge Driven by TONMYA Launch
- Compugen Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- Spruce Biosciences Reports Q3 GAAP EPS Miss and Increased Cash Position
- Aura Biosciences Reports Q3 GAAP EPS of -$0.29 and Strong Cash Position
- CervoMed Reports Third Quarter Financial Results and Cash Runway Through Q3 2027
- Wave Life Sciences Reports Strong Q3 2026 Results with Robust Cash Position and Clinical Progress
- AEye Reports 10-Fold Year-Over-Year Revenue Growth in Q3 2026
- SAB Biotherapeutics Reports Q3 2026 Financial Results and Clinical Progress
- INmune Bio Reports Q3 2026 Net Loss of $4.7 Million and Outlines Regulatory Path for Ebstracel
- Corvus Pharmaceuticals Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- Allogene Therapeutics Reports Q3 2026 Financial Results and Clinical Trial Updates
- LB Pharmaceuticals Reports Q3 GAAP EPS of -$1.79 and Strong Cash Position
- CytomX Therapeutics Reports Q3 2026 Financial Results and Varseta-M Clinical Updates
- Quantum-Si Reports Q3 2026 Results Amid Transition to Proteus Platform
- Adicet Bio Reports Q3 GAAP EPS Miss of $0.17
- Tectonic Therapeutic Reports Q3 GAAP EPS of -$1.08, Exceeding Estimates
- aTyr Pharma Reports Q3 GAAP EPS of -$7.43, Missing Estimates by $3.43
- Voyager Therapeutics Reports Q3 Earnings with EPS Beat but Revenue Miss
- Amylyx Pharmaceuticals Reports Positive Phase 3 LUCIDITY Trial Results and Q3 2026 Financials
- Vir Bio Reports Q3 2026 Financial Results and Gilead Collaboration Details
- OnKure Therapeutics Reports Q3 GAAP EPS of -$0.36 and Strong Cash Runway
- CXApp Reports 77% Sequential Revenue Growth in Q3 2026
- Disc Medicine Reports Q3 GAAP EPS of -$1.53, Exceeding Analyst Expectations
- SCYNEXIS Reports Q3 2026 GAAP EPS of -$0.71, Slightly Exceeding Estimates
- Climb Bio Reports Q3 Non-GAAP EPS of -$0.18, Exceeding Estimates
- Innate Pharma Reports Q3 Revenue Growth and Outlines 2027 Pipeline Milestones
- Damora Therapeutics Reports Q3 GAAP EPS of -$0.40, Exceeding Estimates
- UroGen Reports Significant Revenue Growth and Narrowing Losses in Q3 2026
- uniQure Reports Q3 2026 Financial Results and AMT-130 Clinical Updates
- Ocugen Reports Q3 2026 Financial Results and Clinical Pipeline Progress